Mavyret™ (glecaprevir/pibrentasvir), Zepatier® (elbasvir/grazoprevir), and Vosevi® (sofosbuvir/velpatasvir/voxilaprevir) – Safety update
August 28, 2019 - The FDA announced that the use of Mavyret™ (glecaprevir/pibrentasvir), Zepatier® (elbasvir/grazoprevir), or Vosevi® (sofosbuvir/velpatasvir/voxilaprevir) to treat chronic hepatitis C (CHC) in patients with moderate to severe liver impairment has resulted in rare cases of worsening liver function or liver failure.
Top